ArticleBrain and behavior2026
Financial Toxicity in Neuromyelitis Optica Spectrum Disorder: An ABC-X Mixed-Methods Study.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNeuromyelitis Optica Spectrum Disorder (NMOSD), a rare antoimmune condition, is characterized by a high relapse rate, necessitating long-term maintenance therapy even during clinically stable periods. This prolonged treatment regimen imposes a significant financial burden on patients, which may be greater than that associated with many other chronic diseases. However, data on the impact of financial toxicity (FT) specifically in NMOSD populations remain limited. This study aims to identify factors influencing FT in NMOSD patients using the ABC-X model as a conceptual framework.
methodsA mixed-methods study was conducted in two phases. In the quantitative phase, 210 NMOSD patients were evaluated using four validated scales: (1) Comprehensive Score for FT based on the Patient-Reported Outcomes Measurement Information System (COST-PROM), (2) Fear of Progression Questionnaire-Short form (FoP-Q-SF), (3) Social Support Rating Scale (SSRS), and (4) general self-efficacy scale (GSES). Multivariate linear regression analysis was performed to identify the predictors of FT. In the qualitative phase, 15 NMOSD patients were recruited via purposive sampling and interviewed using a semi-structured format. Interview data were analyzed according to Colaizzi's seven-step phenomenological method.
resultsQuantitative findings indicated that fear of disease progression and lower self-efficacy were significantly associated with higher levels of FT (p < 0.05). Qualitative analysis revealed four thematic categories characterizing the FT experience: (1) direct economic burden stemming from core illness-related stressors, (2) insufficient or suboptimal utilization of available resources, (3) biased appraisal of stressors and maladaptive coping strategies, and (4) emergence of a multidimensional familial crisis state. The convergent results from both methodological approaches reinforced the study conclusions while enriching the overall understanding of FT in the population.
conclusionThis study demonstrates substantial FT among NMOSD patients, influenced by clinical, psychological, and social factors. These findings highlight the importance of integrating FT assessment into routine clinical care. In the Chinese healthcare context, challenges including delayed diagnosis, restricted access to medication, and high costs contribute significantly to this burden. Policy-level interventions should focus on improving disease awareness, expanding treatment accessibility, and reducing financial strain on affected individuals and families.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.